Can Tirzepatide Treat Both Sleep Apnea and Obesity Simultaneously?
Tirzepatide reduced obstructive sleep apnea severity in two phase 3, double-blind, randomized, controlled trials in adults with moderate-to-severe obstructive sleep apnea and obesity. This was not a single trial: trial 1 enrolled participants who were not receiving positive airway pressure (PAP) therapy at baseline, and trial 2 enrolled participants who were already receiving PAP. In both, participants took the maximum tolerated dose of tirzepatide, 10 mg or 15 mg, or placebo for 52 weeks. Tirzepatide lowered the apnea-hypopnea index (AHI), body weight, hypoxic burden, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure, and improved patient-reported sleep impairment and disturbance.
Dr. Kumar’s Take
This is important research for people with obesity-related sleep apnea. In trial 1, where participants were not receiving PAP at baseline, the mean AHI fell by 25.3 events per hour on tirzepatide against 5.3 events per hour on placebo. In trial 2, where participants were receiving PAP at baseline, the mean drop was 29.3 events per hour against 5.5 on placebo. Those are large changes in an objective polysomnographic measure over a year, and the treatment differences of 20.0 and 23.8 events per hour were significant at p<0.001.
Excess adiposity is a major reversible etiologic risk factor for obstructive sleep apnea and its complications. The trials also moved hypoxic burden, hsCRP, and systolic blood pressure in the right direction, which matters to me as much as the AHI itself, because those are the channels through which sleep apnea damages the cardiovascular system.
I would still counsel patients carefully. These are 52-week trials. Nobody has shown what happens to the AHI when the drug stops, the cost is real, and the gastrointestinal side effects, though mostly mild to moderate, are the ones that drive people off treatment. For patients who cannot tolerate PAP or who have not reached meaningful weight loss with lifestyle change alone, this is a genuine option to discuss.
Key Findings
Two phase 3, double-blind, randomized, controlled trials enrolled adults with moderate-to-severe obstructive sleep apnea and obesity, assigned in a 1:1 ratio to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. At baseline, the mean AHI was 51.5 events per hour in trial 1 and 49.5 events per hour in trial 2. Mean BMI was 39.1 and 38.7, respectively.
In trial 1, involving participants not receiving PAP at baseline, the mean change in AHI at week 52 was -25.3 events per hour (95% CI, -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2), p<0.001.
In trial 2, involving participants receiving PAP at baseline, the mean change in AHI was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9), p<0.001.
All prespecified key secondary end points improved significantly with tirzepatide compared with placebo. Those end points were the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, hsCRP concentration, and systolic blood pressure.
Brief Summary
These were two phase 3, double-blind, randomized, controlled trials in adults with moderate-to-severe obstructive sleep apnea and obesity. Participants not receiving PAP at baseline entered trial 1, and those receiving PAP entered trial 2. Each trial randomized participants 1:1 to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change from baseline in the AHI, the number of apneas and hypopneas during an hour of sleep. Key multiplicity-controlled secondary end points included percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, hsCRP, and systolic blood pressure. The trials were funded by Eli Lilly and registered as SURMOUNT-OSA, ClinicalTrials.gov number NCT05412004.
Study Design
The design splits the population by baseline treatment, which I find the most useful feature of this program. Trial 1 tested tirzepatide in people not receiving PAP at baseline. Trial 2 tested it in people who were receiving PAP at baseline. Both trials ran double-blind against placebo for 52 weeks with 1:1 assignment, and both used the AHI as the primary end point. Dosing was to the maximum tolerated dose rather than a fixed 15 mg, so participants received either 10 mg or 15 mg. Key secondary end points were multiplicity-controlled, which protects against false positives when several outcomes are tested.
Results You Can Use
Tirzepatide lowered sleep apnea severity in both settings. Starting from a mean AHI of 51.5 events per hour, participants not receiving PAP at baseline averaged a fall of 25.3 events per hour at 52 weeks, against 5.3 on placebo. Starting from a mean AHI of 49.5 events per hour, participants receiving PAP at baseline averaged a fall of 29.3 events per hour, against 5.5 on placebo.
Body weight fell significantly with tirzepatide compared with placebo, as did hypoxic burden, hsCRP concentration, and systolic blood pressure. Patient-reported sleep impairment and disturbance improved.
The most frequently reported adverse events with tirzepatide were gastrointestinal and mostly mild to moderate in severity.
Why This Matters For Health And Performance
Obstructive sleep apnea affects more than 900 million people worldwide, roughly 40% of whom have moderate-to-severe disease. It is an independent risk factor for cardiovascular disease and produces symptoms such as excessive daytime sleepiness. Until now, treatment has centered on mechanical support during sleep. PAP improves the AHI and reduces symptoms, but its effectiveness depends on adherence, and randomized controlled trials have not shown that PAP reduces cardiovascular events or death. Mandibular advancement is used mainly in people who cannot or will not adhere to PAP, and it is not universally effective. Upper-airway surgery, including hypoglossal nerve stimulation, is invasive and suits selected patients. No drug has been approved for obstructive sleep apnea.
Excess adiposity is a major reversible cause of obstructive sleep apnea and its complications, and clinical guidelines recommend treating obesity in these patients. A medication that lowers weight and the AHI together, along with hypoxic burden, hsCRP, and systolic blood pressure, addresses that cause directly.
How to Apply These Findings in Daily Life
- Consult healthcare providers: Discuss tirzepatide as a treatment option if you have obesity-related sleep apnea
- Consider a comprehensive approach: View sleep apnea treatment as part of overall metabolic health management
- Monitor progress objectively: Track both weight and sleep apnea severity with medical supervision, since the AHI is measured, not felt
- Maintain realistic expectations: These results came after 52 weeks of consistent treatment
- Expect dose individualization: Participants took the maximum dose they tolerated, 10 mg or 15 mg, not a fixed dose
- Plan for long-term treatment: Discuss sustainability and long-term plans with your provider
Limitations To Keep In Mind
These trials ran for 52 weeks, so longer-term outcomes are unknown, including what happens to the AHI if the drug is stopped. The trials enrolled adults with moderate-to-severe obstructive sleep apnea and obesity, and the results should not be extended to sleep apnea patients outside that group. Gastrointestinal adverse events were the most frequent with tirzepatide. The trials were funded by Eli Lilly, the manufacturer, and several authors are employees of the company.
Related Studies And Internal Links
- CPAP vs Oxygen in Obstructive Sleep Apnea Treatment
- CPAP Effects on Blood Pressure in Resistant Hypertension
- Upper Airway Stimulation for Sleep Apnea Treatment
- Sleep Apnea Screening: STOP-Bang Questionnaire Performance
- How to Sleep Better: Science Daily Playbook
FAQs
How does tirzepatide compare to CPAP for treating sleep apnea?
These trials did not pit one against the other. Trial 1 enrolled participants who were not receiving PAP at baseline, and trial 2 enrolled participants who were receiving PAP at baseline.
What are the side effects of tirzepatide for sleep apnea treatment?
The most frequently reported adverse events with tirzepatide in these trials were gastrointestinal in nature and mostly mild to moderate in severity.
Is tirzepatide a permanent cure for sleep apnea?
These trials ran 52 weeks and did not test what happens after the drug is stopped, so nothing here establishes a cure.
Conclusion
Among adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure, and improved sleep-related patient-reported outcomes over 52 weeks. The reductions were seen both in participants who were not receiving PAP at baseline and in those who were.
